Bacteria continue to evolve and develop resistance to existing antibiotics. In this video, Peter shares why, despite this fact, he considers the development new antibiotics “uninvestable,” at least for now.
Though antibiotic resistance is rising, truly “pan-resistant” infections remain extremely rare, so most hospitals still rely on older antibiotics. Regulatory hurdles combined with limited commercial demand deter investment, even though future-proofing our antibiotic supply is crucial. However, a breakthrough product---much like recent obesity drugs---could shift perceptions and spark renewed funding in the field.